Back to top
more

Corvus Pharmaceuticals (CRVS)

(Delayed Data from NSDQ)

$1.47 USD

1.47
3,471

+0.03 (2.08%)

Updated Apr 23, 2024 09:32 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value B Growth D Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 31% (77 out of 252)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Here's Why Corvus (CRVS) is Poised for a Turnaround After Losing -25% in 4 Weeks

by Zacks Equity Research

The heavy selling pressure might have exhausted for Corvus (CRVS) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

Down -18.35% in 4 Weeks, Here's Why Corvus (CRVS) Looks Ripe for a Turnaround

by Zacks Equity Research

Corvus (CRVS) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

Corvus (CRVS) Upgraded to Buy: What Does It Mean for the Stock?

by Zacks Equity Research

Corvus (CRVS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Corvus' (CRVS) Lymphoma Drug Gets Orphan Status, Stock Up

by Zacks Equity Research

Corvus' (CRVS) lead candidate, soquelitinib, gets orphan drug designation in the United States. The company???s shares rise 10.75% on the news.

What Makes Corvus (CRVS) a New Buy Stock

by Zacks Equity Research

Corvus (CRVS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Are Medical Stocks Lagging Corvus Pharmaceuticals (CRVS) This Year?

by Zacks Equity Research

Here is how Corvus Pharmaceuticals (CRVS) and Cue Biopharma, Inc. (CUE) have performed compared to their sector so far this year.

Is Corvus Pharmaceuticals (CRVS) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research

Here is how Corvus Pharmaceuticals (CRVS) and Journey Medical Corporation (DERM) have performed compared to their sector so far this year.

Is Aquestive Therapeutics (AQST) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research

Here is how Aquestive Therapeutics (AQST) and Corvus Pharmaceuticals (CRVS) have performed compared to their sector so far this year.

Corvus Pharma (CRVS) Stock Surges 69.2% in a Week: Here's Why

by Zacks Equity Research

Shares of Corvus Pharma (CRVS) surge 69% this week after the company provided updates on its pipeline development in the first quarter of 2023 earnings release.

Corvus (CRVS) Moves to Buy: Rationale Behind the Upgrade

by Zacks Equity Research

Corvus (CRVS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

The Zacks Analyst Blog Highlights: Condor Hospitality Trust, Corvus Pharmaceuticals, Covenant Logistics and Herc Holdings

by Zacks Equity Research

The Zacks Analyst Blog Highlights: Condor Hospitality Trust, Corvus Pharmaceuticals, Covenant Logistics and Herc Holdings

Sejuti Banerjea headshot

4 Buy-Ranked Stocks that Soared Over 20% in the Past Week

by Sejuti Banerjea

The market remains on its toes as investors digest the ton of information hitting us about now.

Evelo (EVLO) Posts Positive Data from Phase II Psoriasis Study

by Zacks Equity Research

Evelo Biosciences (EVLO) reports encouraging data from a phase II study evaluating EDP1815 for the treatment of mild and moderate psoriasis. Shares up in pre-market trading.

Ultragenyx (RARE) Reports FDA Removal of Clinical Hold on Study

by Zacks Equity Research

Ultragenyx (RARE) and GeneTx Biotherapeutics to start dosing in the phase I/II study on GTX-102 for treating pediatric patients with Angelman syndrome after the FDA removes its clinical hold on the same.

Mirum (MIRM)-Takeda Collaborate for Liver Disease Drug in Japan

by Zacks Equity Research

Mirum (MIRM) signs an agreement with Takeda for developing/commercializing maralixibat for Alagille syndrome, progressive familial intrahepatic cholestasis and biliary atresia, in Japan.

Implied Volatility Surging for Corvus Pharmaceuticals (CRVS) Stock Options

by Zacks Equity Research

Investors need to pay close attention to Corvus Pharmaceuticals (CRVS) stock based on the movements in the options market lately.

BeiGene (BGNE) Scores Third FDA Nod for Brukinsa in Lymphoma

by Zacks Equity Research

The FDA grants accelerated nod to BeiGene's (BGNE) Brukinsa for treating adults with relapsed or refractory marginal zone lymphoma. This marks the third approval for the drug in the United States.

RedHill (RDHL) Down on Unsatisfactory Data From COVID-19 Study

by Zacks Equity Research

RedHill (RDHL) posts preliminary top-line data from a phase II/III study evaluating opaganib in hospitalized patients with severe COVID-19 pneumonia. Stocks falls as the study fails to achieve its goal.

Alnylam (ALNY) Files MAA to EMA for Rare Disease Drug Vutrisiran

by Zacks Equity Research

Alnylam (ALNY) submits a marketing authorization application to the EMA for vutrisiran to treat adult patients with polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis.

BeiGene's (BGNE) BLA for Tislelizumab in ESCC Accepted by FDA

by Zacks Equity Research

The FDA accepts for review BeiGene's (BGNE) BLA for tislelizumab to treat patients with locally advanced/metastatic esophageal squamous cell carcinoma after prior systemic therapy.

Apellis (APLS) Down on Mixed Data From Studies on GA Candidate

by Zacks Equity Research

Apellis (APLS) posts mixed top-line data from the phase III DERBY and OAKS studies testing pegcetacoplan in adults with geographic atrophy secondary to age-related macular degeneration. Stock falls.

Global Blood's (GBT) NDA & sNDA for Oxbryta Get Priority Review

by Zacks Equity Research

The FDA grants priority review to Global Blood's (GBT) sNDA for Oxbryta to treat SCD in children aged four to 11 years, as well as to its NDA for a pediatric weight-based formulation of the drug.

Precision (DTIL) Inks Deal With Tiziana for Cancer Candidate

by Zacks Equity Research

Precision (DTIL) signs an exclusive license agreement with Tiziana to explore the latter's fully human anti-CD3 mAb, foralumab, for treating various cancer indications. Stock up.

BeiGene (BGNE) Gets FDA Nod for Brukinsa Label Expansion

by Zacks Equity Research

The FDA approves BeiGene's (BGNE) Brukinsa for the treatment of adult patients with Waldenstrom's macroglobulinemia. This marks the second approval for the drug in the United States.

Stealth (MITO) Files NDA for Ultra-Rare Disease Candidate

by Zacks Equity Research

Stealth BioTherapeutics (MITO) files a new drug application for elamipretide to the FDA for the treatment of Barth syndrome, an ultra-rare genetic condition.